CLOV: Revenue and membership surged, returning to GAAP profitability and lifting FY2026 guidance
Clover Health reported Q3 revenue growth of 53% YoY and GAAP net income of $6.4 million, with 9M GAAP net income at $61.8 million. The company raised its FY2026 guidance, citing strong Medicare Advantage growth and a 5 Star PPO rating.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise provide fresh, material information that can shift investor sentiment and price action.
Market read
First‑report earnings with significant revenue growth and upgraded guidance, likely to move the stock.
What to watch
Potential regulatory scrutiny of Medicare Advantage contracts could temper upside.
Background
Clover Health reported its Q3 2026 earnings via an SEC 8‑K filing, showing strong revenue growth and profitability.
Ticker impact
Q3 revenue jumped 53% YoY and GAAP net income rose to $6.4M, with FY2026 guidance raised.
likely upside as market prices in strong revenue growth and higher guidance
The 53% revenue surge and improved profitability are fresh data that can drive buying interest.
Market effects
Highlights strength in the Medicare Advantage segment, potentially boosting other health‑tech peers.
U.S. health‑tech sector may see modest rally.
Limited to U.S. markets; no broader global effect.
Counterpoint
If the guidance raise is already priced in, the stock could face a short‑term pullback.
Key entities
- companyClover Health Investments, Corp.
U.S. listed health‑tech firm (ticker CLOV) reporting Q3 results.
